DALLAS CO. HOSP. DIST.
1. Target Overview & Investment Thesis
DALLAS CO. HOSP. DIST. is a 786-bed safety-net/medicaid heavy in DALLAS, TX with $985.4M in net patient revenue and a -100.0% operating margin. The hospital serves a payer mix of 6.9% Medicare, 53.8% Medicaid, and 39.4% commercial.
Thesis: Undervalued. Our ML models identify $72.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -100.0% to -135.0% (+736bps).
| Net Revenue HCRIS | $985.4M |
| Current EBITDA COMPUTED | $-1.40B |
| Operating Margin COMPUTED | -100.0% |
| Occupancy HCRIS | 82.0% |
| Revenue / Bed COMPUTED | $1.3M |
| Net-to-Gross HCRIS | 11.8% |
| Distress Probability ML | 52.4% |
2. Market Context & Competitive Position
TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of -100.0% places it below the state median. Among 37 size-comparable peers (393-1572 beds), the median margin is 4.1%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (393-1572), prioritizing same-state peers. 37 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| DALLAS CO. HOSP. DIST. (Target) | TX | 786 | $985.4M | -100.0% |
| UT MD ANDERSON CANCER CENTER | TX | 721 | $4.90B | -0.8% |
| MEMORIAL HERMANN TEXAS MEDICAL | TX | 1089 | $2.64B | 2.8% |
| THE METHODIST HOSPITAL | TX | 966 | $2.63B | 5.2% |
| TEXAS CHILDRENS HOSPITAL | TX | 863 | $2.50B | -29.9% |
| UT SOUTHWESTERN UNIVERSITY HOS | TX | 737 | $2.28B | -4.6% |
| MEMORIAL HERMANN HOSPITAL SYS | TX | 1417 | $2.15B | 7.3% |
| SCOTT AND WHITE MEMORIAL HOSPI | TX | 616 | $1.85B | -10.5% |
| COOK CHILDRENS MEDICAL CENTER | TX | 423 | $1.51B | 16.5% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $72.5M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $20.7M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $19.7M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $19.5M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $12.0M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $631K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-1.40B |
| + RCM Uplift | +$72.5M |
| Pro Forma EBITDA | $-1.33B |
| Current Margin | -100.0% |
| Pro Forma Margin | -135.0% |
| WC Released (1x) | $37.8M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-2.16B | $-8.53B | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-2.16B | $-10.08B | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-1.94B | $-10.55B | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-1.94B | $-12.08B | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-2.37B | $-8.19B | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-2.37B | $-9.78B | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Elevated Medicaid exposure (53.8%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
| High | Elevated distress probability | Model estimates 52.4% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 37 hospitals with 393-1572 beds
- Same-state prioritization (n=38)
- Comp margins: P25=-10.5% / P50=4.1% / P75=13.1%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.